Antonio Avallone

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Giulia Siravegna, Benedetta Mussolin, Michela Buscarino et al. · Nature Medicine · 2015 · 1.1K citations · Full text

Medicine, Cancer Biology, Oncology +16

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +14

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 254 citations · Full text

Medicine, Oncology, Pharmacology +11

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Clinical Oncology · 2022 · 235 citations

Medicine, Oncology, Pharmacology +17